In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kamada (KMDA – Research Report), with a price target of $11.00. The company’s shares closed last Wednesday at $6.39.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.2% and a 45.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, KalVista Pharmaceuticals, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Kamada is a Moderate Buy with an average price target of $11.00.
The company has a one-year high of $13.33 and a one-year low of $4.40. Currently, Kamada has an average volume of 471.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kamada Ltd. engages in the development and production of pharmaceutical products. It operates through the Proprietary Products segment and the Distribution segment. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the supply of plasma-based products for clinical use. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.